ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/lower-gastrointestinal
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Gastrointestinal (Lower)
65
trial(s) found.
NCT06910657
Advanced
Phase 1
Not yet recruiting
A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors (
VM-002-101
)
oncolytic virus,undisclosed mechanism
Bladder cancer
Breast cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Gastric cancer
Head and neck cancer
Hepatocellular carcinoma
Lung cancer
Melanoma
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Sarcoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
NCT06792695
Advanced
Phase 2
Recruiting
A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (
CANTOR
)
Bevacizumab
Fluorouracil
Irinotecan
Leucovorin
Volrustomig
anti-VEGF monoclonal antibody
antimetabolite
bispecific PD-L1/CTLA4 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,VEGF-targeting
cytotoxic chemotherapy
fluoropyrimidine
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,VEGF-targeting
therapeutic modality,bispecific antibody
topoisomerase inhibitor
Colorectal cancer
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
NCT06789172
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Multicenter, Dose-escalation and Cohort Expansion Study of OKN4395, a Triple Antagonist of EP2, EP4, and DP1 Prostanoid Receptors, as Monotherapy and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors (
INVOKE
)
anti-PD-1 monoclonal antibody
prostaglandin EP2/EP4/DP1 receptor inhibitor
Colorectal cancer
Dedifferentiated liposarcoma
Fibrosarcoma
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Pancreatic adenocarcinoma
Sarcoma
Solid tumour
Solitary fibrous tumour
Undifferentiated pleomorphic sarcoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
WA
6009 - Nedlands - Linear Clinical Research
NCT06751329
Advanced
Phase 1
Recruiting
A Phase I, Multicentre, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors (
DM002001
)
Colorectal cancer
Endometrial cancer
Ovarian cancer
Prostate cancer
NSW
2500 - Wollongong - Wollongong Hospital
NCT06750094
Advanced
Phase 3
Recruiting
A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (
OrigAMI-3
)
anti-EGFR monoclonal antibody
anti-VEGF monoclonal antibody
bispecific cMET/EGFR antibody
Colorectal adenocarcinoma
NSW
2139 - Concord - Concord Repatriation General Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Warringal Private Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06625775
Advanced
Phase 1
Recruiting
A Phase 1a/1b Study of the PI3Kα:RAS Breaker BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study) (
TBBO10203-101
)
PI3K alpha-RAS breaker
Breast cancer
Colorectal cancer
HER2-positive breast cancer
Non-small cell lung cancer
RAS-mutant colorectal cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06617169
Advanced
Phase 1
Recruiting
Open Label, Phase 1a, Dose-Escalation Study Evaluating the Safety of Fractionated MNPR-101-PCTA-177Lu Dosing in the Treatment of Solid Tumor Cancers (
MNPR101-Lu-1-01
)
177Lu-anti-uPAR radioconjugate
Bladder cancer
Colorectal cancer
Gastric cancer
Lung cancer
Ovarian cancer
Pancreatic cancer
Solid tumour
Triple-negative breast cancer
Urothelial carcinoma
VIC
3051 - North Melbourne - Melbourne Theranostic Innovation Centre
NCT06599502
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0022 Monotherapy and in Combination With Anti-cancer Agents in Participants With Tumours Harbouring a KRASG12D Mutation (
ALAFOSS-01
)
KRAS G12D inhibitor
Colorectal cancer
Non-small cell lung cancer
Pancreatic adenocarcinoma
Solid tumour
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06585488
Advanced
Phase 1
Recruiting
A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplifications (
BGB-53038-101
)
pan-KRAS inhibitor
Cancer
Colorectal cancer
Gastric cancer
Non-squamous non-small-cell lung cancer
Oesophageal adenocarcinoma
Pancreatic adenocarcinoma
Solid tumour
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06428409
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers (
9999-02A
)
anti-Trop2 antibody-drug conjugate
Biliary tract cancer
Colorectal cancer
Pancreatic adenocarcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6009 - Nedlands - One Clinical Research
NCT06400472
Advanced
Phase 1
Recruiting
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
anti-FR-alpha antibody-drug conjugate
Cervical cancer
Colorectal cancer
Endometrial cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Triple-negative breast cancer
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06343402
Advanced
Phase 1
Recruiting
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects with Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - the ONKORAS-101 Study (
TBBO8520-101
)
KRAS G12C inhibitor
Colorectal adenocarcinoma
Non-small cell lung cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
NCT06252649
Advanced
Phase 3
Recruiting
Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301) (
CodeBreaK-301
)
KRAS G12C/NRAS G12C/HRAS G12C inhibitor
anti-EGFR monoclonal antibody
anti-VEGF monoclonal antibody
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4350 - Toowoomba - Toowoomba Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
NCT06242470
Advanced
Phase 1
Recruiting
A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors (
CP-MGC026-01
)
anti-B7H3 antibody-drug conjugate
Bladder cancer
Cancer
Castrate-resistant prostate cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Melanoma
Non-small cell lung cancer
Pancreatic cancer
Platinum resistant ovarian cancer
Sarcoma
Small-cell lung cancer
Solid tumour
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06050707
Curative
Phase 2
Recruiting
MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach (
MAESTRO
)
radiotherapy
Anal squamous cell carcinoma
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT05855200
Curative
Phase 3
Recruiting
A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer (
AZUR-2
)
anti-PD-1 monoclonal antibody
Colon adenocarcinoma
Colorectal adenocarcinoma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT05759728
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2a, Multicenter, Open-Label, Dose Escalation and Expansion Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Adult Subjects With Metastatic Colorectal Cancer (
CNA3103-001
)
autologous CAR-T-cell therapy,LGR5-targeting
Colorectal adenocarcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT05462236
Advanced
Phase 2
Recruiting
A Phase II Open Label, Dose-finding run-in and Cohort Expansion Study to Evaluate the Safety, Tolerability and Effectiveness of Tinodasertib in Combination With Pembrolizumab or Irinotecan in Metastatic Colorectal Cancer (
AUM001-2001-MK3475-D65
)
MNK1/2 inhibitor
anti-PD-1 monoclonal antibody
topoisomerase inhibitor
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2500 - Wollongong - Wollongong Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4217 - Benowa - Pindara Private Hospital
NCT05411133
Advanced
Phase 1
Recruiting
A Phase 1, First-in-human Study of Cabotamig (ARB202), Bispecific Antibody to CDH17 and CD3 in Advanced Gastrointestinal Malignancies (
A001
)
bispecific T-cell engager,CDH17-targeting
Cholangiocarcinoma
Colorectal adenocarcinoma
Gastric cancer
Gastrointestinal cancer
Hepatocellular carcinoma
Oesophageal adenocarcinoma
Pancreatic cancer
NSW
2217 - Kogarah - St George Private Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT05253651
Advanced
Phase 3
Recruiting
An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer (
MOUNTAINEER-03
)
ERBB2 inhibitor,third generation
anti-EGFR monoclonal antibody
anti-ERBB2 monoclonal antibody
anti-VEGF monoclonal antibody
Colorectal cancer
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
NCT05086692
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors (
ABILITY-1
)
IL-2 superkine
Acral lentiginous melanoma
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Cutaneous basal cell carcinoma
Cutaneous melanoma
Cutaneous squamous cell carcinoma
Endometrial carcinoma
Epithelial Ovarian Cancer
Fallopian tube cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Merkel cell carcinoma
Mucosal melanoma
Non-melanoma skin cancer
Non-squamous non-small-cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic adenocarcinoma
Pleural mesothelioma
Primary peritoneal serous carcinoma
Skin cancer
Solid tumour
Squamous non-small-cell lung cancer
Triple-negative breast cancer
dMMR solid cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
QLD
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
NCT05067283
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors (
KANDLELIT-001
)
KRAS G12C inhibitor
Colorectal cancer
NOT Non-small cell lung cancer
Non-small cell lung cancer
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3168 - Clayton - Monash Medical Centre
NZ
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (COMPLETED)
NCT04956640
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors (
LOXO-RAS-20001
)
KRAS G12C inhibitor
Biliary tract cancer
Colorectal cancer
Endometrial cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT04929223
Advanced
Phase 1
Recruiting
A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) (
WO42758
)
Atezolizumab
Bevacizumab
CDK7 inhibitor
Cetuximab
Divarasib
Inavolisib
KRAS G12C inhibitor
KRAS inhibitor
PI3K alpha inhibitor
SY-5609
Tiragolumab
anti-EGFR monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
anti-VEGF monoclonal antibody
cancer therapy
cancer therapy,CDK7-targeting
cancer therapy,EGFR-targeting
cancer therapy,KRAS-targeting
cancer therapy,KRAS G12C-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,TIGIT-targeting
cancer therapy,VEGF-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,EGFR-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,VEGF-targeting
Colorectal adenocarcinoma
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT04895709
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors (
CA052-002
)
anti-CCR8 monoclonal antibody
anti-PD-1 monoclonal antibody
taxane
Cervical cancer
Clear cell renal cell carcinoma
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Microsatellite stable colorectal cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic adenocarcinoma
Triple-negative breast cancer
Urothelial carcinoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - One Clinical Research
NCT04801095
Advanced
Phase 1
Recruiting
A Phase I, Open-label, Multicenter, Dose-escalation and Dose-expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of WM-S1-030 in Patients With Advanced Solid Tumors (
WMS1030-101
)
mutant receptor tyrosine kinase inhibitor
Cholangiocarcinoma
Colorectal cancer
Head and neck cancer
Lung cancer
Pancreatic cancer
Solid tumour
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT04644068
Advanced
Phase 1 / Phase 2
Recruiting
A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (
PETRA
)
PARP1-selective inhibitor
Biliary tract cancer
Bladder cancer
Breast cancer
Cervical cancer
Colorectal cancer
Endometrial cancer
Gastric cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Small-cell lung cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT04585750
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (
PMV-586-101
)
mutant p53 reactivator,Y220C-selective
Bladder cancer
Breast cancer
Colorectal cancer
Endometrial cancer
HER2-negative breast cancer
HER2-positive breast cancer
Head and neck cancer
Lung cancer
Non-small cell lung cancer
Ovarian cancer
Prostate cancer
Small-cell lung cancer
Triple-negative breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - One Clinical Research
NCT04449874
Advanced
Phase 1
Recruiting
A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation (
GO42144
)
KRAS G12C inhibitor
Colorectal cancer
Non-small cell lung cancer
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
WA
6009 - Nedlands - Linear Clinical Research
NA
NA
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT04429542
Advanced
Phase 1
Recruiting
First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors (
BCA101X1101
)
bifunctional EGFR/TGF-beta fusion protein
Anal squamous cell carcinoma
Carcinoma
Colorectal cancer
Cutaneous squamous cell carcinoma
Epithelial Ovarian Cancer
Head and neck cancer
Head and neck squamous cell carcinoma
Pancreatic cancer
Squamous cell carcinoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT04140526
Advanced
Phase 1 / Phase 2
Recruiting
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (
PRESERVE-001
)
anti-CTLA-4 monoclonal antibody
anti-PD-1 monoclonal antibody
Adenoid cystic carcinoma
Breast cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Head and neck cancer
Melanoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Salivary gland cancer
Sarcoma
Small-cell lung cancer
Solid tumour
Urothelial carcinoma
NSW
2305 - New Lambton Heights - Newcastle Private Hospital
QLD
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT03947385
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions (
IDE196-001
)
PKC inhibitor
Colorectal cancer
Cutaneous melanoma
Solid tumour
Uveal melanoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
NCT03175224
Advanced
Phase 2
Recruiting
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (
SPARTA
)
MET inhibitor,type 1
Cancer
Central nervous system cancer
Colon adenocarcinoma
Gastric cancer
Gastroesophageal junction adenocarcinoma
Glioblastoma
Kidney cancer
Lung cancer
MET:alteration
MET:fusion
Non-small cell lung cancer
Pancreatic cancer
Solid tumour
Thyroid cancer
NSW
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT02628067
Advanced
Phase 2
Recruiting
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158) (
KEYNOTE-158
)
anti-PD-1 monoclonal antibody
Anal cancer
Biliary tract cancer
Cancer
Cervical cancer
Cholangiocarcinoma
Colorectal cancer
Endometrial cancer
Endometrial carcinoma
Lung carcinoid tumour
Mesothelioma
Neuroendocrine tumour
Pancreatic neuroendocrine tumour
Salivary gland cancer
Salivary gland carcinoma
Small-cell lung cancer
Solid tumour
Thyroid cancer
Vulval cancer
NSW
2109 - North Ryde - Macquarie University Hospital
ACTRN12625000203459
Advanced
Phase 1 / Phase 2
Not yet recruiting
An open-label, multicenter, Phase I/IIa study assessing the safety and efficacy of EGFR targeted EDVsTM carrying cytotoxic drug PNU-159682 plus concurrent immunomodulatory adjuvant non-targeted EDVs carrying a-galactosyl ceramide in subjects with advanced EGFR-expressing cancers who have failed second-line therapy or where first- and/or second-line therapy is not appropriate (EGFR EDV-D682/GC Trial) (
ENG19
)
EnGeneIC Dream Vector-nanocells-delivered,EGFR-targeting
Colorectal cancer
Kidney cancer
Lung cancer
Mesothelioma
Non-small cell lung cancer
Pancreatic adenocarcinoma
Solid tumour
Triple-negative breast cancer
NSW
2060 - North Sydney - Mater Hospital
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
ACTRN12623001333606
Curative
Phase 2
Not yet recruiting
The Novel use of Labetuzumab as Adjuvant Immunotherapy in Patients with Primary Colon Adenocarcinoma with Intact PELPK Binding Motif in their CEACAM5 gene in a Phase II clinical trial regarding the Development of Metachronous Liver Metastases (i.e., those at ‘high-risk’ of metachronous CRCLMs) (
CCaLM
)
anti-CEACAM5 monoclonal antibody
Colon adenocarcinoma
NSW
2217 - Kogarah - St George Hospital
ACTRN12623000874617
Advanced
Phase 2
Recruiting
Phase II single arm study to explore the efficacy of cetuximab (in combination with irinotecan based treatment) in advanced stage RAS/BRAF wild-type right-sided colorectal cancer with high AREG/EREG expression (
Biomarcer-2
)
anti-EGFR monoclonal antibody
topoisomerase inhibitor
Colorectal cancer
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3011 - Footscray - Footscray Hospital
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
3844 - Traralgon - Latrobe Regional Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12620000757910
Curative
Not Applicable
Recruiting
Functional imaging-guided radiotherapy dose escalation in rectal adenocarcinoma: a feasibility study (
FIGURE-rectal
)
radiotherapy
Rectal adenocarcinoma
QLD
4575 - Birtinya - Sunshine Coast University Hospital
ACTRN12619000566134
Advanced
Phase 2
Recruiting
OXTOX
: Can Oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study
PDE4 inhibitor
platinum-based antineoplastic agent
Colorectal cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2500 - Wollongong - Wollongong Hospital
2640 - Albury - Border Medical Oncology Research Unit
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
ACTRN12617001087347
Curative
Phase 2
Recruiting
A randomized, placebo-controlled phase II trial of Simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer (
SPAR
)
HMG-CoA reductase inhibitor
placebo
Rectal adenocarcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2200 - Bankstown - Bankstown-Lidcombe Hospital
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
VIC
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4215 - Southport - Gold Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06614192
Advanced
Phase 3
Not recruiting
AndroMETa-CRC-064: An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing ABBV-400 Monotherapy to LONSURF (Trifluridine and Tipiracil) Plus Bevacizumab in Subjects With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer (
M24-064
)
Tipiracil Hydrochloride
Trifluridine
anti-VEGF monoclonal antibody
anti-cMET antibody-drug conjugate
antimetabolite
thymidine phosphorylase inhibitor
Colorectal cancer
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT06509906
Advanced
Phase 1
Suspended
An Open Label, Multicenter, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the PARP1 Inhibitor M9466 in Combination With Topoisomerase 1 Inhibitor-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511) (
MS202650-0001
)
PARP1-selective inhibitor
Colorectal adenocarcinoma
NOT Colorectal adenocarcinoma
Solid tumour
NSW
2217 - Kogarah - St George Private Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
NCT06194877
Advanced
Phase 1
Terminated
A Phase 1b, Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 With Panitumumab in Patients With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers (
BGB-3245-EGFR-001
)
RAF dimer inhibitor
anti-EGFR monoclonal antibody
Colorectal adenocarcinoma
Pancreatic adenocarcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT06024174
Advanced
Phase 1 / Phase 2
Terminated
Phase 1/2 Open-label Study of BMS-986466 in Combination With Adagrasib With or Without Cetuximab in Participants With KRAS G12C-mutant Advanced Solid Tumors (
CA126-0015
)
KRAS G12C inhibitor
SHP2 inhibitor
anti-EGFR monoclonal antibody
Biliary tract cancer
Colorectal cancer
Non-small cell lung cancer
Pancreatic adenocarcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
NCT05954871
Advanced
Phase 1
Active not recruiting
A Phase Ib Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Patients With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Patients With Metastatic Colorectal Cancer (
GO44272
)
EGFR inhibitor,third generation
SHP2 inhibitor
anti-EGFR monoclonal antibody
Colorectal cancer
Non-small cell lung cancer
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre
NCT05867303
Advanced
Phase 1
Active not recruiting
A Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Immunogenetic and Efficacy of RC198 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors (
RC198-G001
)
undisclosed fusion protein
Clear cell renal cell carcinoma
Colorectal cancer
Head and neck squamous cell carcinoma
Melanoma
Non-small cell lung cancer
Urothelial carcinoma
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT05858736
Advanced
Phase 1
Active not recruiting
Safety, Pharmacokinetics (PK) and Efficacy of AI-061, A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC-392 (Anti-CTLA-4) Antibodies in Advanced Solid Tumors: An Open-Label Phase 1 Study (
PRESERVE-009
)
anti-CTLA-4 monoclonal antibody
anti-PD-1 monoclonal antibody
Adenocarcinoma
Anal cancer
Biliary tract cancer
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Endometrial cancer
Fallopian tube cancer
Gastric cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Melanoma
Non-small cell lung cancer
Oesophageal cancer
Primary peritoneal serous carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT05743036
Advanced
Phase 1
Active not recruiting
A Phase 1/2, Open-Label, Multi-Center Study of ZN-c3 Administered in Combination With Encorafenib and Cetuximab in Adults With Metastatic Colorectal Cancer (
ZN-c3-016
)
BRAF V600 inhibitor
WEE1 inhibitor
anti-EGFR monoclonal antibody
Colorectal cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT05694936
Advanced
Phase 2
Unknown
A Phase II Randomised Controlled Trial to Determine the Efficacy of Combining the HDAC Inhibitor Sodium Valproate With EGFR Monoclonal Antibody (Panitumumab or Cetuximab) Maintenance in the First-line Treatment of Patients With RAS Wild Type Metastatic Colorectal Cancer (CRC) (
VADER
)
HDAC inhibitor
anti-EGFR monoclonal antibody
Colorectal cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3199 - Frankston - Peninsula Health Frankston Hospital
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
NCT05609370
Advanced
Phase 1 / Phase 2
Active not recruiting
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer (
BGB-A317-LBL-007-201
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
anti-VEGF monoclonal antibody
Colorectal cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2650 - Wagga Wagga - Riverina Cancer Care Centre
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4217 - Benowa - Pindara Private Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6009 - Nedlands - One Clinical Research
6150 - Murdoch - Fiona Stanley Hospital
NCT05605522
Advanced
Phase 1
Active not recruiting
A Phase 1 Study of [225Ac]-FPI-2059 in Adult Participants With NTSR1-Expressing Advanced, Metastatic and/or Recurrent Solid Tumours (
FPI-2059-101
)
radioconjugate,NTSR1-targeting
Colorectal cancer
Ewing sarcoma
Gastric cancer
Head and neck squamous cell carcinoma
Pancreatic adenocarcinoma
Prostate cancer
Solid tumour
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
NCT05551117
Advanced
Phase 2
Completed
A Phase 2, Open-label, Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors (
Tamarack
)
anti-B7H3 antibody-drug conjugate
Anal cancer
Carcinoma
Castrate-resistant prostate cancer
Head and neck squamous cell carcinoma
Laryngeal squamous cell carcinoma
Melanoma
Non-small cell lung cancer
Prostate cancer
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Squamous cell carcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT05546476
Advanced
Phase 2
Active not recruiting
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER, CACHEXIA, AND ELEVATED CONCENTRATIONS OF GDF-15, FOLLOWED BY AN OPTIONAL OPEN-LABEL TREATMENT PERIOD (PROACC -1) (
PROACC-1
)
anti-GDF15 monoclonal antibody
placebo
Colorectal cancer
Non-small cell lung cancer
Pancreatic cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
NCT05500508
Advanced
Phase 1 / Phase 2
Terminated
A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer (
AMXT1501-102
)
polyamine transport inhibitor
Breast cancer
Cancer
Central nervous system cancer
Cervical cancer
Colorectal cancer
Endometrial cancer
Gastric cancer
H3K27M-mutant glioma
Head and neck cancer
Malignant glioma
Melanoma
Mesothelioma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Papillary thyroid cancer
Pleural mesothelioma
Solid tumour
NSW
2145 - Westmead - The Children's Hospital at Westmead
NCT05462717
Advanced
Phase 1
Active not recruiting
Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors (
RMC-6291-001
)
KRAS G12C inhibitor
Colorectal cancer
Non-small cell lung cancer
Pancreatic adenocarcinoma
Solid tumour
NSW
2228 - Miranda - Southside Cancer Care Centre
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
NCT05425940
Advanced
Phase 3
Active not recruiting
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (
STELLAR-303
)
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
MET/VEGFR2/AXL/MER inhibitor
anti-PD-L1 monoclonal antibody
Colorectal cancer
NSW
2200 - Bankstown - Bankstown-Lidcombe Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.9016 - Dunedin - Dunedin Hospital
NCT05363605
Advanced
Phase 1 / Phase 2
Terminated
A Phase 1/2 Study of [225Ac]-FPI-1966, [111In]-FPI-1967, and Vofatamab in Participants With FGFR3-expressing Advanced, Inoperable, Metastatic and/or Recurrent Solid Tumours (
FPI-1966-101
)
radioconjugate,FGFR3-targeting
Bladder cancer
Breast cancer
Colorectal cancer
Gastric cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Lung cancer
Ovarian cancer
Solid tumour
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05330429
Advanced
Phase 2
Terminated
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) (
ELEVATE-CRC
)
anti-CD47 monoclonal antibody
anti-VEGF monoclonal antibody
Colorectal cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - GenesisCare North Shore Private Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2228 - Miranda - Southside Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
NCT05328908
Advanced
Phase 3
Active not recruiting
A Phase 3, Randomized, Open-label Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants With Later-lines of Metastatic Colorectal Cancer (
RELATIVITY-123
)
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
Tipiracil Hydrochloride
Trifluridine
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
antimetabolite
thymidine phosphorylase inhibitor
Colorectal adenocarcinoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2650 - Wagga Wagga - Riverina Cancer Care Centre
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05217446
Advanced
Phase 2
Active not recruiting
A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND CETUXIMAB PLUS PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE IN PARTICIPANTS WITH PREVIOUSLY UNTREATED BRAF V600E-MUTANT, MSI H/DMMR METASTATIC COLORECTAL CANCER (
SEAMARK
)
BRAF V600 inhibitor
anti-EGFR monoclonal antibody
anti-PD-1 monoclonal antibody
Colorectal cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT05198934
Advanced
Phase 3
Active not recruiting
A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (
CodeBreak300
)
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
KRAS G12C/NRAS G12C/HRAS G12C inhibitor
anti-EGFR monoclonal antibody
Colorectal cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT03906331
Advanced
Approved for marketing
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
RET-selective inhibitor
RET inhibitor
Selpercatinib
cancer therapy
cancer therapy,RET-targeting
Breast cancer
Colon adenocarcinoma
Medullary thyroid cancer
Non-small cell lung cancer
Pancreatic cancer
Papillary thyroid cancer
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4032 - Chermside - The Prince Charles Hospital
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT03900442
Advanced
Phase 1
Unknown status
Phase 1 Pharmacodynamic and Pharmacokinetic Study of the Geranylgeranyltransferase I Inhibitor PTX-100 (GGTI-2418) in Patients With Advanced Malignancies (
PTX-100-PD-012017
)
geranylgeranyl transferase inhibitor
Colorectal cancer
Gastric cancer
Multiple myeloma
Pancreatic adenocarcinoma
Peripheral T-cell lymphoma
VIC
3002 - East Melbourne - Epworth Freemasons
ACTRN12618001480279
Advanced
Phase 2
Status unknown
Alternating oxaliplatin and irinotecan doublet schedules versus continuous doublet chemotherapy in previously untreated metastatic colorectal cancer: A Treatment of Recurrent and Advanced Colorectal Cancer registry-based prospective randomised trial (
ALT-TRACC
)
platinum-based antineoplastic agent
topoisomerase inhibitor
Colorectal cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3011 - Footscray - Footscray Hospital
3021 - St Albans - Western Health - Sunshine Hospital
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit
3844 - Traralgon - Latrobe Regional Hospital
ACTRN12617001190392
Advanced
Phase 1 / Phase 2
Status unknown
An open label phase IB/II, non-randomised, dose-finding, safety and tolerability study of Panitumumab, Irinotecan, Trifluridine/Tipiracil in RAS wild-type patients with metastatic colorectal cancer (
PIT-Study
)
Tipiracil Hydrochloride
Trifluridine
anti-EGFR monoclonal antibody
antimetabolite
thymidine phosphorylase inhibitor
topoisomerase inhibitor
Colorectal cancer
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Flinders Medical Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (37)
Active not recruiting (12)
Terminated (5)
Not yet recruiting (3)
Status unknown (2)
Not recruiting (1)
Suspended (1)
Unknown (1)
Completed (1)
Approved for marketing (1)
Unknown status (1)
Recruitment Country and State
VIC (48)
NSW (46)
SA (22)
QLD (21)
WA (14)
NZ (6)
Phase
Phase 1 (24)
Phase 1 / Phase 2 (16)
Phase 2 (15)
Phase 3 (8)
Trial Type
Advanced (60)
Curative (5)
Cancer Therapy Class
PD-1/PD-L1
32%
EGFR
29%
PD-1
26%
VEGF
18%
KRAS
17%
KRAS G12C
14%
MET
8%
PD-L1
6%
FGFR
6%
FGFR3
6%
RET
6%
CTLA4
5%
ERBB2
5%
PI3Kalpha
5%
SHP2
5%
BRAF
5%
RAF
5%
FGFR1
5%
FGFR1/2/3
5%
FGFR2
5%
FGFR4
5%
KIT
5%
PDGFR
5%
VEGFR
5%
Trop2
3%
HRAS G12C
3%
NRAS G12C
3%
B7H3
3%
PARP
3%
PARP1-selective
3%
BRAF V600
3%
LAG3
3%
prostaglandin DP1 receptor
2%
prostaglandin EP2 receptor
2%
prostaglandin EP4 receptor
2%
KRAS G12D
2%
FR-alpha
2%
DPD
2%
orotate phosphoribosyltransferase
2%
LGR5
2%
MNK
2%
CDH17
2%
IL-2
2%
CDK7
2%
TIGIT
2%
CCR8
2%
mutant receptor tyrosine kinase
2%
ER
2%
oestrogen axis
2%
TP53
2%
TP53 Y220C
2%
ALK
2%
MEK
2%
PKC
2%
ROS1
2%
CEACAM5
2%
PDE4
2%
HMG-CoA reductase
2%
WEE1
2%
HDAC
2%
NTSR1
2%
AR
2%
CYP17A1
2%
androgen axis
2%
GDF15
2%
polyamine transport
2%
AXL
2%
MER
2%
VEGFR2
2%
CD47
2%
geranylgeranyl transferase
2%
Facility
3000 - Melbourne - Peter MacCallum Cancer Centre (19)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (16)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (11)
5042 - Bedford Park - Flinders Medical Centre (10)
5011 - Woodville South - The Queen Elizabeth Hospital (9)
2050 - Camperdown - Chris O'Brien Lifehouse (8)
3199 - Frankston - Peninsula Health Frankston Hospital (7)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (7)
3004 - Melbourne, Southbank - Alfred Health (6)
6009 - Nedlands - Linear Clinical Research (6)
3168 - Clayton - Monash Medical Centre (6)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (6)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (6)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (5)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (5)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (5)
3065 - Fitzroy - St Vincent's Hospital Melbourne (5)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (5)
2500 - Wollongong - Wollongong Hospital (4)
3021 - St Albans - Western Health - Sunshine Hospital (4)
6009 - Nedlands - One Clinical Research (4)
4102 - Woolloongabba - Princess Alexandra Hospital (4)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (4)
3280 - Warrnambool - South West Healthcare, Warrnambool Base Hospital, Oncology Unit (4)
6150 - Murdoch - Fiona Stanley Hospital (4)
3002 - East Melbourne - Epworth Freemasons (3)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (3)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (3)
2109 - North Ryde - Macquarie University Hospital (3)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (3)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (3)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (3)
3128 - Box Hill - Box Hill Hospital - Eastern Health (3)
2139 - Concord - Concord Repatriation General Hospital (2)
2031 - Randwick - Scientia Clinical Research Ltd (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
4217 - Benowa - Pindara Private Hospital (2)
2217 - Kogarah - St George Private Hospital (2)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (2)
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation (2)
2170 - Liverpool - Liverpool Hospital (2)
4215 - Southport - Tasman Oncology (2)
3011 - Footscray - Footscray Hospital (2)
3066 - Epping - Northern Hospital (2)
3844 - Traralgon - Latrobe Regional Hospital (2)
2640 - Albury - Border Medical Oncology Research Unit (2)
2200 - Bankstown - Bankstown-Lidcombe Hospital (2)
NZ.3210 - Hamilton - Waikato Hospital (2)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (2)
5112 - Elizabeth Vale - Lyell McEwin Hospital (2)
2650 - Wagga Wagga - Riverina Cancer Care Centre (2)
2228 - Miranda - Southside Cancer Care Centre (2)
2065 - St Leonards - GenesisCare North Shore Private Hospital (2)
3084 - Heidelberg - Warringal Private Hospital (1)
3051 - North Melbourne - Melbourne Theranostic Innovation Centre (1)
4350 - Toowoomba - Toowoomba Hospital (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
NA
2305 - New Lambton Heights - Newcastle Private Hospital (1)
2640 - Albury - Albury Wodonga Regional Cancer Centre (1)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
2060 - North Sydney - Mater Hospital (1)
2217 - Kogarah - St George Hospital (1)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
4215 - Southport - Gold Coast University Hospital (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
3690 - Wodonga - Border Medical Oncology at Wodonga Regional Cancer Centre (1)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
2145 - Westmead - The Children's Hospital at Westmead (1)
3002 - Melbourne - Peter MacCallum Cancer Centre, East Melbourne campus (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
4032 - Chermside - The Prince Charles Hospital (1)
Cancer Type
Cancer
Gastrointestinal cancer
Lower gastrointestinal cancer
Solid tumour
Colorectal cancer
Thoracic cancer
Lung cancer
Respiratory tract cancer
Upper gastrointestinal cancer
Pancreatobiliary cancer
Pancreatic cancer
Non-small cell lung cancer
Gynaecological cancer
Head and neck cancer
Urogenital cancer
Colorectal adenocarcinoma
Gastric cancer
Gastroesophageal cancer
Ovarian cancer
Breast cancer
HPV-related cancer
HPV16-positive cancer
Viral-related cancer
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Hepatobiliary cancer
Cervical cancer
Melanoma
Head and neck squamous cell carcinoma
Endometrial cancer
Kidney cancer
Oesophageal cancer
Bladder cancer
Male genital cancers
Prostate cancer
Biliary tract cancer
Carcinoma
Clear cell renal cell carcinoma
Breast adenocarcinoma
Triple-negative breast cancer
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Hepatocellular carcinoma
Sarcoma
Anal cancer
Urothelial carcinoma
Colon adenocarcinoma
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Mesothelioma
Endocrine gland cancer
Thyroid cancer
Epithelial Ovarian Cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Cholangiocarcinoma
Skin cancer
HER2-positive breast cancer
Non-squamous non-small-cell lung cancer
Oesophageal adenocarcinoma
Castrate-resistant prostate cancer
Prostate adenocarcinoma
Anal squamous cell carcinoma
Cutaneous melanoma
Cutaneous squamous cell carcinoma
Endometrial carcinoma
Fallopian tube cancer
Non-melanoma skin cancer
Peritoneal cancer
Pleural mesothelioma
Primary peritoneal serous carcinoma
Squamous cell carcinoma
Salivary gland cancer
Central nervous system cancer
Glioma
High-grade glioma
Malignant glioma
Neurological cancer
Rectal adenocarcinoma
Differentiated thyroid carcinoma
Papillary thyroid cancer
Dedifferentiated liposarcoma
Fibrosarcoma
Liposarcoma
Soft tissue sarcoma
Solitary fibrous tumour
Undifferentiated pleomorphic sarcoma
RAS-mutant colorectal cancer
High-grade serous ovarian cancer
Ovarian adenocarcinoma
Ovarian serous carcinoma
Platinum resistant ovarian cancer
Acral lentiginous melanoma
Biomarker-defined solid tumour
Cutaneous basal cell carcinoma
MSI-H/dMMR solid tumour
Merkel cell carcinoma
Mucosal melanoma
Squamous non-small-cell lung cancer
dMMR solid cancer
Microsatellite stable colorectal cancer
Non-microsatellite instability-high colorectal cancer
HER2-negative breast cancer
Adenoid cystic carcinoma
Cancer Solid tumour Carcinoma
Uveal melanoma
Glioblastoma
MET:alteration
MET:fusion
Gastro-entero-pancreatic neuroendocrine tumour
Lung carcinoid tumour
Neuroendocrine tumour
Pancreatic neuroendocrine tumour
Salivary gland carcinoma
Vaginal and vulvar cancer
Vulval cancer
Adenocarcinoma
Bone cancer
Ewing family of tumours
Ewing sarcoma
Primitive neuroectodermal tumour
Laryngeal squamous cell carcinoma
H3K27M-mutant glioma
Medullary thyroid cancer
Haematological malignancy
Lymphoma
Multiple myeloma
Non-Hodgkin's lymphoma
Peripheral T-cell lymphoma
Plasma cell disorder
T-cell lymphoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy